ImmunoCellular (IMUC.OB) Develops Method for Optimal Vaccine Production
ImmunoCellular Therapeutics is a clinical-stage biotechnology company focused on developing immune-based therapies for the treatment of various cancers. The company recently completed phase I trials for its lead product candidate ICT-107, and today announced that it has developed an innovative means to manufacture the dendritic cell-based vaccine for the treatment of glioblastoma multiforme (GBM), a common type of brain tumor. ImmunoCellular co-developed the method with the Clinical Cell and Vaccine Production Facility at the University of Pennsylvania. The method is a closed-bag system designed to produce highly potent dendritic cells from white blood cells collected from patients to use in…